Equities analysts expect that Immune Design Corp. (NASDAQ:IMDZ) will announce sales of $620,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Immune Design Corp.’s earnings, with estimates ranging from $400,000.00 to $840,000.00. Immune Design Corp. reported sales of $8.21 million during the same quarter last year, which indicates a negative year-over-year growth rate of 92.4%. The business is expected to announce its next earnings results on Wednesday, November 8th.

On average, analysts expect that Immune Design Corp. will report full year sales of $620,000.00 for the current financial year, with estimates ranging from $7.00 million to $11.00 million. For the next year, analysts anticipate that the company will post sales of $16.54 million per share, with estimates ranging from $15.08 million to $18.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover Immune Design Corp..

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million.

A number of equities analysts have issued reports on the stock. ValuEngine cut shares of Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research report on Saturday. Wells Fargo & Company cut shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. Royal Bank Of Canada assumed coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price for the company. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.75.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/immune-design-corp-imdz-expected-to-post-quarterly-sales-of-620000-00-2.html.

Shares of Immune Design Corp. (NASDAQ IMDZ) opened at 5.20 on Tuesday. The stock’s market cap is $133.22 million. The company’s 50-day moving average is $9.81 and its 200 day moving average is $8.59. Immune Design Corp. has a 52 week low of $4.50 and a 52 week high of $13.05.

In other Immune Design Corp. news, major shareholder Leo Guthart bought 10,000 shares of the business’s stock in a transaction on Thursday, October 19th. The stock was bought at an average price of $6.09 per share, for a total transaction of $60,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.70% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in IMDZ. Victory Capital Management Inc. grew its holdings in shares of Immune Design Corp. by 2.1% during the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock worth $19,281,000 after buying an additional 40,010 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Immune Design Corp. by 2.7% during the second quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock worth $7,412,000 after buying an additional 20,000 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Immune Design Corp. by 118.7% during the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock worth $5,175,000 after buying an additional 288,009 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Immune Design Corp. by 37.9% during the second quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after buying an additional 144,408 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Immune Design Corp. by 0.4% during the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after buying an additional 1,699 shares in the last quarter. Institutional investors own 51.47% of the company’s stock.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp. (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.